In Vitro Diagnostics (IVD) Quality Control Market Size, Share, Growth, Industry Analysis, Trends and Dynamics, By Types (Quality Controls, Whole Blood-based Controls, Serum/Plasma-based Controls, Urine-based Controls, Other IVD Quality Controls, Data Management Solutions, Quality Assurance Services), By Applications (Hospitals, Laboratory, Research Institutes and Academics, Others), Regional Insights and Forecast to 2035
- Last Updated: 08-November-2026
- Base Year: 2025
- Historical Data: 2021 - 2024
- Region: Global
- Format: PDF
- Report ID: GGI101382
- SKU ID: 30450451
- Pages: 114
Download FREE Sample
In Vitro Diagnostics (IVD) Quality Control Market Size
The global In Vitro Diagnostics (IVD) Quality Control Market was valued at USD 1353.6 Million in 2025 and is expected to reach USD 1416.48 Million in 2026 and USD 1482.4 Million in 2027. It is forecast to climb to USD 2132.65 Million by 2035, advancing at a CAGR of 4.65% across the 2026-2035 forecast period.
Growth here is steady rather than spectacular, which suits a market tied to compulsory laboratory discipline. Close to 70% of clinical decisions draw on laboratory results, so every analyzer run needs verification. Independent third-party controls now represent roughly 55% of purchasing decisions, as laboratories look for bias detection that does not depend on the reagent maker. Digital quality monitoring has reached nearly 40% of mid-sized laboratories.
![]()
In the US In Vitro Diagnostics (IVD) Quality Control Market, demand is anchored by CLIA-driven documentation rules and a high density of testing. The country accounts for about 82% of North American activity, and roughly 64% of large hospital laboratories run automated multi-rule monitoring. Expanding molecular and toxicology menus keep widening control requirements across reference laboratories.
Key Findings
- Market Size: Starting at $1416.48M in 2026, projected to touch $1482.4M in 2027 to $2132.65M by 2035 at a CAGR of 4.65%.
- Growth Drivers: Chronic disease testing contributes 34% of demand momentum, stricter accreditation mandates 27%, and automation-linked quality monitoring 21% across laboratories.
- Trends: Third-party controls reach 55% usage, digital peer comparison adoption stands near 38%, and multi-analyte controls take 31% of new purchases.
- Key Players: Bio-Rad Laboratories, Inc., Thermo Fisher Scientific Inc., Roche Diagnostics, Randox Laboratories Ltd., Abbott Laboratories Inc. & more.
- Regional Insights: North America holds 39%, Europe 28%, Asia-Pacific 25%, and Middle East & Africa 8%, reflecting mature compliance in the West and fast laboratory build-out elsewhere.
- Challenges: Budget pressure affects 41% of laboratories, commutability gaps concern 26%, and skilled quality staff shortages touch 22% of facilities.
- Industry Impact: Effective controls reduce repeat testing by 18%, lower proficiency failures by 23%, and support 30% faster accreditation audits.
- Recent Developments: About 45% of launches target molecular controls, 29% emphasize digital connectivity, and 17% extend stability for decentralized sites.
Quality control is one of the few laboratory spending lines that behaves almost like a utility. A test cannot be released without proof that the analyzer is performing, which keeps consumption tied to patient volumes. Roughly 60% of control usage is recurring, and about 25% of laboratories rotate suppliers only when accreditation reviews demand it.
Buyers are also changing what they value. Beyond the control material itself, around 33% of purchasing teams now weigh software, peer-group benchmarking and audit-ready reporting equally with vial performance. That shift is rewarding suppliers who bundle materials, data tools and advisory support into one quality framework.
![]()
In Vitro Diagnostics (IVD) Quality Control Market Trends
The most visible shift is the move toward independent, analyzer-agnostic controls. Laboratories running several instrument brands want one consistent yardstick, and about 55% now choose third-party materials for at least part of their menu. Alongside this, multi-analyte controls that cover dozens of markers in a single vial are winning share, with close to 31% of new purchasing decisions favoring them because they cut handling steps by nearly 20% and reduce material waste.
Digital integration is the second defining trend. Peer-group comparison platforms and middleware-linked quality dashboards are used by about 38% of laboratories, and facilities that adopt them report up to 25% fewer undetected shifts in assay performance. Meanwhile, molecular diagnostics controls are growing faster than chemistry controls, now representing over 22% of new product activity, as infectious disease panels and oncology testing push demand for run-level assurance in decentralized and high-throughput settings alike.
In Vitro Diagnostics (IVD) Quality Control Market Dynamics
Growth in molecular and decentralized testing controls
Molecular assays and near-patient testing open a clear space for suppliers that can deliver stable, ready-to-use controls. Molecular panels now represent about 22% of new control development, yet fewer than 40% of decentralized testing sites follow structured quality monitoring. That gap invites compact formats, longer shelf life and simplified data capture designed for non-specialist operators. Emerging economies add further room, since roughly 35% of newly accredited laboratories there are still building formal quality systems and typically start with bundled control and training packages. Suppliers that pair materials with remote support can win lasting relationships in these segments.
Rising demand for accreditation-ready quality assurance
Regulators and accrediting bodies increasingly expect documented, traceable quality performance, and that expectation translates directly into control consumption. Around 58% of laboratories report that accreditation requirements are the primary reason they expanded control coverage, while about 47% have raised the frequency of control runs after adding new assays. Rising chronic disease screening adds volume, with testing workloads in many laboratories climbing by more than 10% in a typical cycle. As automation consolidates testing into fewer, larger laboratories, each analyzer failure becomes costlier, strengthening the business case for rigorous and continuous quality monitoring.
| Market Driver | Impact Rank | Contribution | 2026-2028 | 2029-2031 | 2032-2035 |
|---|---|---|---|---|---|
| Rising chronic and infectious disease testing volumes | High | 2.10% | High | High | Medium |
| Stricter accreditation and regulatory quality mandates | High | 1.70% | High | High | Medium |
| Expanding molecular, immunoassay and toxicology test menus | Medium | 1.30% | Medium | High | High |
| Laboratory automation and digital QC monitoring adoption | Medium | 0.90% | Medium | Medium | High |
| Growth of point-of-care and decentralized testing | Low | 0.60% | Low | Medium | Medium |
| Others | Lowest | 0.40% | Low | Low | Low |
| Total Driver Contribution | 7.00% |
RESTRAINTS
"Budget pressure on laboratory quality spending"
Laboratories operate under tight reimbursement conditions, and quality control is often reviewed when savings are sought. Nearly 41% of laboratory managers say budget limits have pushed them to extend control lot usage or reduce the number of control levels. Standardization gaps add friction, since about 26% of laboratories report that controls behave differently across analyzer platforms, which complicates purchasing consolidation. Supply of human-derived raw materials is also uneven, and roughly 15% of suppliers cite sourcing constraints as a limit on lot size and delivery consistency.
| Market Restraint | Impact Rank | Negative CAGR Impact | 2026-2028 | 2029-2031 | 2032-2035 |
|---|---|---|---|---|---|
| Laboratory budget pressure and reimbursement constraints | High | -1.05% | High | High | Medium |
| Commutability and standardization gaps across analyzer platforms | Medium | -0.70% | Medium | Medium | Medium |
| Supply constraints in human-derived raw materials | Low | -0.40% | Medium | Low | Low |
| Others | Lowest | -0.20% | Low | Low | Low |
| Total Restraint Impact | -2.35% |
CHALLENGES
"Rising costs and skills shortages in quality management"
Operational complexity is the main test for both suppliers and laboratories. Cold-chain logistics and stability requirements raise handling costs, and about 19% of control shipments need specialized temperature management. On the laboratory side, roughly 22% of facilities struggle to recruit staff trained in statistical quality methods, which limits how fully digital tools are used. Regulatory documentation also differs by jurisdiction, and close to 28% of suppliers say multi-region compliance slows product launches and increases the cost of maintaining several control portfolios.
Segmentation Analysis
The market divides by what is being controlled and who is using it. Material-based controls still form the base, holding close to 66% of activity, while data management and assurance services together contribute about 26% and are gaining as laboratories value interpretation as much as consumables. On the user side, hospitals and independent laboratories dominate purchasing at nearly 79% combined, with research and academic settings adding a smaller but more specialized demand layer.
By Type
Quality Controls
General quality controls remain the largest category at roughly 24% share, supported by their use across chemistry, immunoassay and coagulation workflows. Laboratories buy them in multiple levels to verify accuracy across the measuring range, and about 62% of routine analyzers are checked at two or more levels daily. Their appeal lies in broad compatibility and predictable lot-to-lot performance.
Whole Blood-based Controls
Whole blood-based controls hold about 11% share and are central to hematology, glycated hemoglobin and blood gas testing. Because cell stability is difficult to maintain, shelf life is the main buying criterion, and nearly 30% of laboratories name it as the top selection factor. Point-of-care expansion is lifting demand for formats that tolerate transport and variable storage.
Serum/Plasma-based Controls
Serum and plasma-based controls account for around 22% share, reflecting their role in clinical chemistry, hormones, tumor markers and infectious disease serology. Multi-analyte products dominate this group, with about 48% of purchases covering ten or more analytes per vial. Demand is steady because these controls match the sample matrix most laboratories process every day.
Urine-based Controls
Urine-based controls represent about 9% share and serve urinalysis, drug-of-abuse screening and renal marker testing. Growth is tied to toxicology and workplace screening programs, where roughly 35% of laboratories run controls at several cutoff levels. Automated urine sediment analyzers also encourage purchases of controls that verify both chemical and particle counting performance.
Other IVD Quality Controls
This category covers cerebrospinal fluid, molecular, microbiology and specialty controls and holds close to 8% share. Molecular controls are the fastest-moving element, now representing over 40% of purchases within the group, as laboratories need run-level verification for amplification and sequencing workflows. Custom and low-volume products also sustain niche suppliers.
Data Management Solutions
Data management solutions command about 14% share and are expanding as laboratories digitize quality records. Software that applies multi-rule logic and peer-group comparison is used by nearly 38% of facilities, and adopters report about 25% fewer unnoticed analytical shifts. Integration with laboratory information systems remains the decisive purchasing factor for larger networks.
Quality Assurance Services
Quality assurance services, including proficiency testing and consulting, hold about 12% share. Roughly 70% of accredited laboratories participate in at least one external assessment scheme, and demand rises whenever new accreditation standards are introduced. Services appeal to smaller laboratories that lack in-house expertise, often generating recurring engagement beyond the initial contract.
By Application
Hospitals
Hospitals lead with about 41% share because they run continuous, high-volume testing and must satisfy rigorous accreditation reviews. Around 66% of hospital laboratories operate integrated analyzer lines, which favors bundled control programs. Emergency and critical care testing adds pressure for rapid, reliable verification, making hospitals early adopters of automated quality monitoring tools.
Laboratory
Independent and reference laboratories account for roughly 38% share and are intensely cost and efficiency focused. Consolidation has concentrated testing into larger networks, where nearly 57% of volume is processed in centralized facilities. These buyers negotiate multi-site contracts, prefer third-party controls for cross-platform consistency, and invest steadily in digital peer-comparison and audit-ready reporting.
Research Institutes and Academics
Research institutes and academic centers hold about 14% share, driven by assay development, biomarker validation and training programs. About 44% of purchases here involve specialty or customized controls rather than standard routine products. Funding cycles make demand less predictable, yet collaboration with diagnostic developers keeps the segment relevant for innovation.
Others
Other users, including blood banks, public health agencies, physician offices and occupational testing providers, represent roughly 7% share. Point-of-care adoption in clinics is the main growth source, although only around 40% of such sites follow structured control schedules today, which signals room for simplified products and guided workflows.
![]()
In Vitro Diagnostics (IVD) Quality Control Market Regional Outlook
Regional performance reflects regulatory maturity, laboratory density and healthcare investment. North America leads with 39% share, Europe follows with 28%, Asia-Pacific holds 25%, and Middle East & Africa accounts for the remaining 8%, together making up 100% of the market. Mature regions generate stable replacement demand, while emerging regions add new laboratories and first-time adoption of formal quality systems.
North America
North America holds about 39% of the market, supported by strict federal quality rules and a dense network of hospital and reference laboratories. Around 64% of large laboratories use automated multi-rule monitoring, and third-party controls are specified in nearly 60% of purchasing tenders. Strong molecular and toxicology testing volumes continue to broaden control requirements, while consolidation of laboratory networks favors suppliers offering integrated materials and software.
Europe
Europe represents roughly 28% of the market, shaped by harmonized diagnostic regulation and strong accreditation culture. About 72% of laboratories follow structured external quality assessment, which sustains steady control and service demand. Germany, France and the United Kingdom together contribute close to 55% of regional activity. Public procurement pressure encourages tendering, yet quality documentation requirements keep premium controls and data tools relevant for most buyers.
Asia-Pacific
Asia-Pacific accounts for about 25% of the market and is the most dynamic region for new laboratory capacity. Hospital expansion and screening programs are lifting test volumes, and nearly 35% of newly accredited laboratories are building formal quality systems for the first time. China, Japan and India represent roughly 70% of regional demand. Local manufacturing is growing, increasing price competition while widening access to controls.
Middle East & Africa
Middle East & Africa holds about 8% of the market, with demand concentrated in Gulf countries and South Africa, which together contribute around 60% of regional activity. Investment in private hospital chains and national accreditation programs is raising control adoption, yet fewer than 45% of laboratories in many areas follow routine quality schedules. Imports supply most products, so distribution partnerships remain essential.
List of Key In Vitro Diagnostics (IVD) Quality Control Market Companies Profiled
- Helena Laboratories
- Ortho Clinical Diagnostics, Inc.
- Bio-Rad Laboratories, Inc.
- Technopath Clinical Diagnostics
- Thermo Fisher Scientific Inc.
- Sero as
- Abbott Laboratories Inc.
- Roche Diagnostics
- Seracare Life Sciences, Inc.
- Randox Laboratories Ltd.
Top Companies with Highest Market Share
- Bio-Rad Laboratories, Inc.: Leads with about 26% share, backed by a broad third-party control and data management portfolio.
- Thermo Fisher Scientific Inc.: Holds roughly 14% share through wide laboratory reach and expanding multi-analyte and molecular controls.
Investment Analysis and Opportunities
Capital is flowing toward three areas: molecular controls, digital quality platforms and regional manufacturing. Molecular products draw about 30% of new development budgets, reflecting the steady growth of infectious disease and oncology testing. Software and analytics attract roughly 25% of investment, as laboratories seek automated rule checking and peer benchmarking that cut manual review time by close to 20%. Emerging markets offer further openings, since about 35% of newly accredited laboratories still need structured quality programs. Partnerships between control makers and analyzer manufacturers are also increasing, with nearly 40% of recent collaborations centered on integrated workflows. Investors tend to favor suppliers with recurring consumable revenue streams, diversified raw material sourcing and strong compliance records.
New Products Development
Product innovation is focused on stability, breadth and connectivity. New liquid-ready controls are extending shelf life by up to 20%, easing storage demands for decentralized sites. Multi-analyte formats now cover broader panels, and about 31% of recent launches combine ten or more markers in one vial to reduce handling steps. Molecular controls account for nearly 45% of new introductions, with synthetic and whole-process materials replacing scarce clinical specimens. Connectivity is another priority, as roughly 29% of new products ship with barcode-linked lot data and direct software integration. Suppliers are also refining commutability, aiming to reduce platform-specific variation that currently concerns about 26% of laboratories.
Recent Developments
- March 2024– Bio-Rad Laboratories broadened its multi-analyte control range: The extended portfolio added wider molecular and immunoassay coverage, increasing the number of targets per control by about 15%. It helps laboratories consolidate vials, reduce handling steps and strengthen independent verification across mixed-platform testing environments.
- August 2024– Randox Laboratories upgraded its peer-comparison program: The enhanced program improved data turnaround and reporting depth, with participation rising by roughly 12%. Laboratories gain faster identification of performance drift, supporting accreditation readiness and more confident decisions on assay reliability.
- November 2024– Thermo Fisher Scientific expanded digital quality analytics: New dashboard capabilities allowed multi-site networks to view control performance in one place, lowering manual review effort by nearly 20%. The move reflects growing demand for connected quality oversight in consolidated laboratory groups.
- February 2025– Roche Diagnostics linked quality control data with laboratory middleware: The integration automated rule evaluation and documentation, reducing out-of-control event response time by about 22%. It strengthens analyzer-to-software workflows and supports laboratories facing heavier test volumes and audit expectations.
- June 2025– Abbott Laboratories introduced longer-stability immunoassay controls: The refreshed controls extended usable shelf life by around 18%, helping smaller and decentralized laboratories reduce waste and reorder frequency while keeping consistent verification across demanding immunoassay menus.
Report Coverage
This report examines the In Vitro Diagnostics (IVD) Quality Control Market through market structure, demand behavior, competitive positioning and regional performance. It evaluates seven product types, led by quality controls with about 24% share, followed by serum/plasma-based controls at 22%, and covers four application groups where hospitals account for roughly 41% of demand. Regional analysis spans North America at 39%, Europe at 28%, Asia-Pacific at 25% and Middle East & Africa at 8%. The study profiles ten manufacturers, with the top two holding a combined share of about 40%. It reviews drivers, restraints, opportunities and challenges using percentage-based indicators, highlights technology shifts such as the 38% digital quality platform adoption rate, and assesses investment direction, product development priorities and recent strategic actions. Supply conditions, regulatory influences and laboratory purchasing behavior are also considered to give decision makers a balanced, practical view of how quality assurance demand is evolving.
In Vitro Diagnostics (IVD) Quality Control Market Report Coverage
| REPORT COVERAGE | DETAILS | |
|---|---|---|
|
Market Size Value In |
USD 1416.48 Million in 2026 |
|
|
Market Size Value By |
USD 2132.65 Million by 2035 |
|
|
Growth Rate |
CAGR of 4.65% from 2026 - 2035 |
|
|
Forecast Period |
2026 - 2035 |
|
|
Base Year |
2025 |
|
|
Historical Data Available |
Yes |
|
|
Regional Scope |
Global |
|
|
Segments Covered |
By Type :
By Application :
|
|
|
To Understand the Detailed Market Report Scope & Segmentation |
||
Download FREE Sample
Frequently Asked Questions
-
What value is the In Vitro Diagnostics (IVD) Quality Control Market expected to touch by 2035?
The global In Vitro Diagnostics (IVD) Quality Control Market is expected to reach USD 2132.65 Million by 2035.
-
What CAGR is the In Vitro Diagnostics (IVD) Quality Control Market expected to exhibit by 2035?
The In Vitro Diagnostics (IVD) Quality Control Market is expected to exhibit a CAGR of 4.65% by 2035.
-
Who are the top players in the In Vitro Diagnostics (IVD) Quality Control Market?
Helena Laboratories, Ortho Clinical Diagnostics, Inc., Bio-Rad Laboratories, Inc., Technopath Clinical Diagnostics, Thermo Fisher Scientific Inc., Sero as, Abbott Laboratories Inc., Roche Diagnostics, Seracare Life Sciences, Inc., Randox Laboratories Ltd.
-
What was the value of the In Vitro Diagnostics (IVD) Quality Control Market in 2025?
In 2025, the In Vitro Diagnostics (IVD) Quality Control Market value stood at USD 1353.6 Million.
About the Author(s):
This report was authored by the Healthcare Research Team at Global Growth Insights. The team specializes in pharmaceuticals, biotechnology, medical devices, diagnostics, digital health, healthcare services, and life sciences. Their expertise includes market sizing, regulatory analysis, competitive benchmarking, and healthcare trend forecasting to support strategic investment and business growth.
Our Clients
Download FREE Sample